HighGravityDataRegeneron Pharmaceuticals — Apr 29, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000872589-26-000014
Showing in the filing
Share repurchase program authorized
“$3.0 billion”
Period
No period stated
Measure
Declared action
Source
Prose
All guidance in this release · 16
Share repurchase program authorized
“$3.0 billion”
Cash dividend declared for FY2026
“$0.94 per share”
Cash dividend
“$0.94 per share”
GAAP R&D for FY2026
“$6.450–$6.680 billion”
Non-GAAP R&D for FY2026
“$5.900–$6.100 billion”
GAAP SG&A for FY2026
“$2.860–$3.040 billion”
Non-GAAP SG&A for FY2026
“$2.500–$2.650 billion”
GAAP gross margin on net product sales
“79%–80%”
GAAP gross margin on net product sales for FY2026
“77%–78%”
Non-GAAP gross margin on net product sales for FY2026
“83%–84%”
Non-GAAP COCM for FY2026
“$940 million–$1.020 billion”
GAAP COCM for FY2026
“$955 million–$1.035 billion”
Capital expenditures
“$1.100–$1.300 billion”
Capital expenditures for FY2026
“$1.100–$1.200 billion”
GAAP effective tax rate for FY2026
“12%–14%”
Non-GAAP effective tax rate for FY2026
“13%–15%”
Exhibit 99.1 · the passage around this item
… earlier in the release
net sales decreased 10% to $941 million • GAAP EPS of $6.75, including $0.82 negative impact from IPR&D; non-GAAP EPS (a) of $9.47, including $0.80 negative impact from IPR&D • EYLEA HD approved by FDA as first and only injectable anti-VEGF with dosing intervals up to 5 months for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) • Dupixent approved by FDA and European Commission (EC) for young children with chronic spontaneous urticaria (CSU); also approved by FDA as first and only medicine for allergic fungal rhinosinusitis (AFRS) • Otarmeni ™ (lunsotogene parvec) approved by FDA as first and only gene therapy for genetic hearing loss; Regeneron to provide Otarmeni for free in U.S. • New $3.0 billion share repurchase program authorized Tarrytown, New York (April 29, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced financial results for the first quarter of 2026 and provided a business update. "In the first quarter of this year, we were able to achieve strong double-digit growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. "Additionally, we recently entered into an agreement with the U.S. government that aims to make progress toward lowering drug prices for American patients by promoting more balanced pricing with other wealthy nations — an approach for which Regeneron has long advocated." Financial Highlights ($ in millions, except per share data) Q1 2026 Q1 2025 % Change Total revenues $ 3,605 $ 3,029 19 % GAAP net income $ 727 $ 809 (10 %) GAAP net income per share - diluted $ 6.75 $ 7.27 (7 %) Non-GAAP net income (a) $ 1,040 $ 928 12 % Non-GAAP net income per share - diluted (a) $ 9.47 $ 8.22 15 % 1 "Regeneron delivered stron
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.